Skip to main content

Johnson & Johnson posts 23% rise in third-quarter profit

Johnson & Johnson on Tuesday posted a 22.9% rise in third-quarter profit, boosted by demand for its cancer drugs Darzalex and Imbruvica.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.